Endo Pharmaceuticals Inc. V. Actavis
United States Court of Appeals for the Federal Circuit ______________________ ENDO PHARMACEUTICALS INC., MALLINCKRODT LLC, Plaintiffs-Appellees v. ACTAVIS LLC, FKA ACTAVIS INC., ACTAVIS SOUTH ATLANTIC LLC, TEVA PHARMACEUTICALS USA, INC., Defendants-Appellants ______________________ 2018-1054 ______________________ Appeal from the United States District Court for the District of Delaware in No. 1:14-cv-01381-RGA, Judge Richard G. Andrews. ______________________ Decided: May 3, 2019 ______________________ MARTIN JAY BLACK, Dechert LLP, Philadelphia, PA, ar- gued for plaintiffs-appellees. Also represented by SHARON K. GAGLIARDI; BLAKE GREENE, Austin, TX; JONATHAN LOEB, Mountain View, CA; ROBERT RHOAD, Princeton, NJ. JEFFREY J. TONEY, Kasowitz, Benson, Torres & Fried- man LLP, Atlanta, GA, for plaintiff-appellee Mallinckrodt LLC. Also represented by RODNEY R. MILLER, PAUL GUNTER WILLIAMS. 2 ENDO PHARM. INC. v. ACTAVIS LLC JOHN C. O'QUINN, Kirkland & Ellis LLP, Washington, DC, argued for defendants-appellants. Also represented by WILLIAM H. BURGESS; CHARLES A. WEISS, ERIC H. YECIES, Holland & Knight, LLP, New York, NY. ______________________ Before WALLACH, CLEVENGER, and STOLL, Circuit Judges. Opinion for the court filed by Circuit Judge WALLACH. Dissenting opinion filed by Circuit Judge STOLL. WALLACH, Circuit Judge. Appellees Endo Pharmaceuticals Inc. (“Endo Pharma- ceuticals”) and Mallinckrodt LLC (“Mallinckrodt”) (collec- tively, “Endo”) sued Appellants Actavis LLC, Actavis South Atlantic LLC, and Teva Pharmaceuticals USA, Inc. (collec- tively, “Actavis”) in the U.S. District Court for the District of Delaware (“District Court”), alleging that two Abbrevi- ated New Drug Applications filed by Actavis infringed claims 1–6 (“the Asserted Claims”) of Mallinckrodt’s U.S. Patent No. 8,871,779 (“the ’779 patent”), which Endo Phar- maceuticals licenses.
[Show full text]